Interstitial lung disease in systemic sclerosis: where do we stand?
Interstitial lung disease (ILD) is common in systemic sclerosis (SSc) patients and despite recent advances in the treatment is, at present, the major cause of death. Today, an early diagnosis of ILD is possible, and is mandatory to improve the prognosis of the disease. Pulmonary function tests and h...
Main Authors: | Susanna Cappelli, Silvia Bellando Randone, Gianna Camiciottoli, Amato De Paulis, Serena Guiducci, Marco Matucci-Cerinic |
---|---|
Format: | Article |
Language: | English |
Published: |
European Respiratory Society
2015-09-01
|
Series: | European Respiratory Review |
Online Access: | http://err.ersjournals.com/content/24/137/411.full |
Similar Items
-
Immunosuppression for interstitial lung disease in systemic sclerosis
by: Susanna Cappelli, et al.
Published: (2013-09-01) -
Potential Role of JAK Inhibitors in the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease: A Narrative Review from Pathogenesis to Real-Life Data
by: Elisa Fiorentini, et al.
Published: (2022-12-01) -
The Role of Bronchoalveolar Lavage in Systemic Sclerosis Interstitial Lung Disease: A Systematic Literature Review
by: Martina Orlandi, et al.
Published: (2022-12-01) -
The “myth” of loss of angiogenesis in systemic sclerosis: a pivotal early pathogenetic process or just a late unavoidable event?
by: Marco Matucci-Cerinic, et al.
Published: (2017-07-01) -
Vascular Leaking, a Pivotal and Early Pathogenetic Event in Systemic Sclerosis: Should the Door Be Closed?
by: Cosimo Bruni, et al.
Published: (2018-09-01)